tirzepatide surmount after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial tirzepatide maximum weight loss surmount

Unlike intramuscular delivery, theres essentially no risk of nerve injury

and infections associated with injection in a peripheral joint space such as the knee, shoulder or ankle

[1] [2] While vomiting itself is not a typical symptom of medullary thyroid carcinoma, patients should promptly report any neck mass, hoarseness, difficulty swallowing, or shortness of breath

For active adultsespecially those recovering from injury, managing joint pain, or working toward long-term functional independencethis matters

Patients with IBS-C (constipation-dominant) may experience worsening symptoms within weeks of starting therapy, while those with IBS-D (diarrhea-dominant) sometimes report improvement in urgency and stool frequency

Kaur M, Singh A, Kumar B, Singh SK, Bhatia A, Gulati M, et al